PROVIDER PROFILE · NPI 1023098282
Natalie Vanek
MEDICARE UTILIZATION · PART B · 2024
No data available for this provider in 2024.
PRESCRIBING · PART D · 2024
Total Rx claims
4,658
Beneficiaries
—
Total drug cost
$5.3M
Distinct drugs
98
Brand share
50.5%
Top prescribed drugs
Dolutegravir Sodium448 claims
Darunavir/Cobicistat382 claims
Dolutegravir/Rilpivirine210 claims
Atorvastatin Calcium209 claims
Bictegrav/Emtricit/Tenofov Ala181 claims
QUALITY · MIPS · 2024
No data available for this provider in 2024.
REFERRAL NETWORK
Where Natalie Vanek's patients come from & go
Directional shared-patient flow from Medicare claims — who sends patients to this provider (inbound) and where this provider's patients go next (outbound). 0 inbound referrers · 3 outbound destinations.
Receives referrals from
Inbound — who sends patients here
No inbound pairs above the suppression threshold.
Refers patients to
Outbound — where patients go next
| Physician | Patients | Visits |
|---|---|---|
| LEGACY COMMUNITY HEALTH SERVICES, INC | 117 | 264 |
| Laboratory Corporation Of America Clinical Laboratory · Houston, TX | 37 | 106 |
| Laboratory Corporation Of America Holdings Clinical Laboratory · Burlington, NC | 26 | 43 |
Source: CMS Physician Shared Patient Patterns (30-day window, Medicare FFS). Direction = a beneficiary seen by the first provider, then the second, within 30 days; a proxy for referral, not a documented referral. Pairs with fewer than 11 shared beneficiaries are suppressed.
CROSS-REFERENCE